The Gujarat Kidney & Super Speciality IPO is a Mainboard IPO worth ₹250.80 crore, offering investors exposure to a fast-growing multispecialty hospital chain focused on Gujarat. Operated by Gujarat Kidney & Super Speciality Ltd., the company delivers secondary and tertiary healthcare services through a network of hospitals catering to both critical and lifestyle-related medical needs.
With a strong presence in renal sciences and multispecialty care, the company positions itself as a regional healthcare platform with scalable growth ambitions.
What Does Gujarat Kidney & Super Speciality Do?
Gujarat Kidney & Super Speciality operates seven multispecialty hospitals and four pharmacies across Gujarat. The hospitals collectively offer hundreds of beds and cover a wide range of medical services, including nephrology, urology, orthopaedics, general surgery, obstetrics, cardiology, diabetology, and critical care.
Its dominance in kidney-related treatments, supported by experienced doctors and modern infrastructure, provides a niche advantage in a competitive healthcare landscape.
Gujarat Kidney & Super Speciality IPO Details
The Gujarat Kidney & Super Speciality IPO opens for subscription on December 22, 2025, and closes on December 24, 2025. The issue is a 100% fresh issue, indicating that the proceeds will directly support business expansion. The IPO price band is fixed between ₹108 and ₹114 per share, with a tentative listing scheduled for December 30, 2025 on BSE and NSE.
Financial Growth Snapshot
The company has reported sharp growth in revenue and profitability over recent years. From negligible income in FY23, it has scaled operations rapidly, delivering strong EBITDA and PAT margins in FY25. High return ratios such as ROE and ROCE reflect efficient capital utilisation, while debt levels remain relatively low — a positive signal for a hospital business.
Why the IPO Proceeds Matter
IPO funds will be used for hospital acquisitions, setting up a new facility in Vadodara, purchasing advanced robotic equipment, and reducing borrowings. This strategy reflects a clear focus on capacity expansion and inorganic growth, which could significantly enhance patient volumes and long-term revenue visibility.
Valuation & Peer Comparison
At the upper price band, the Gujarat Kidney & Super Speciality IPO valuation implies a P/E of around 39x based on FY25 earnings. While this appears higher than some listed peers, it is supported by strong margins, high return ratios, and an aggressive growth pipeline.
Strengths and Key Risks
The company benefits from specialised medical expertise, an asset-light regional model, and rising healthcare demand in Gujarat. However, execution risks from acquisitions and sensitivity to hospital occupancy levels remain key concerns for investors.
Should You Consider This IPO?
The Gujarat Kidney & Super Speciality IPO offers exposure to a profitable and expanding healthcare platform with strong regional dominance. It may suit long-term investors comfortable with valuation premiums and execution risks in exchange for growth potential in India’s healthcare sector.
Post a Comment